Abstract
This discussion paper addresses the safety of HIV cure studies, particularly those involving stopping antiretroviral therapy, known as an analytic treatment interruption (ATI) in the context of the SARS-CoV-2 pandemic. More than 30 studies listed on ClinicalTrials.gov include an ATI and many others were planned to begin over the next 12 months but most were halted due to the COVID-19 pandemic. We consider the ethics, risks and practical considerations to be taken into account before re-opening HIV cure clinical trials, noting the specific risks of ATI in the context of circulating SARS-CoV-2.
All Keywords
【저자키워드】 SARS-CoV-2, HIV cure, Analytical treatment interruption (ATI) COVID-19, 【초록키워드】 Treatment, HIV, pandemic, COVID-19 pandemic, clinical trials, risk, Antiretroviral therapy, circulating, include, the SARS-CoV-2, 【제목키워드】 COVID-19, Treatment, HIV, therapy, Research,
【저자키워드】 SARS-CoV-2, HIV cure, Analytical treatment interruption (ATI) COVID-19, 【초록키워드】 Treatment, HIV, pandemic, COVID-19 pandemic, clinical trials, risk, Antiretroviral therapy, circulating, include, the SARS-CoV-2, 【제목키워드】 COVID-19, Treatment, HIV, therapy, Research,